Homology Medicines, Inc. is looking to raise up to $100.0 million in an IPO on the Nasdaq Global Select Market.
The Bedford, Mass.-based genetic medicines company plans to list its shares under the FIXX symbol, according to a securities filing.
The company aims to use its gene editing technology to develop HMI-102, which is meant to treat a rare inherited disorder known as phenylketonuria. Funds raised will be used for those efforts.
Merrill Lynch Pierce Fenner & Smith Inc., Cowen and Co. LLC, Evercore Group LLC, and BTIG LLC are acting as underwriters for the offering.
The company also disclosed the financial terms of a previously announced licensing agreement with Novartis AG for the commercialization of its gene-editing technology for treating a certain blood disorder and eye diseases.
Under the deal, Homology Medicines received $35.0 million upfront from the Swiss drugmaker and issued additional shares of its series B preferred stock to Novartis for $10.0 million.
Homology is also eligible to receive up to a total of $960.0 million in milestone payments for the licensed products.
